{"id":"https://openalex.org/W7220839703","doi":"https://doi.org/10.3389/fphar.2026.1938259","title":"Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system","display_name":"Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system","publication_year":2026,"publication_date":"2026-10-07","ids":{"openalex":"https://openalex.org/W7220839703","doi":"https://doi.org/10.3389/fphar.2026.1938259","pmid":"https://pubmed.ncbi.nlm.nih.gov/42908723","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13683131"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1938259","doi":"https://doi.org/10.3389/fphar.2026.1938259","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938259","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938259/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938259/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5157814188","display_name":"Feng Zhai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Feng Zhai","raw_affiliation_strings":["Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159786925","display_name":"Hongyang Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hongyang Li","raw_affiliation_strings":["Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157810839","display_name":"Chaolan Jiang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chaolan Jiang","raw_affiliation_strings":["Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157851916","display_name":"Jianpeng Mao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianpeng Mao","raw_affiliation_strings":["Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Anhui Wannan Rehabilitation Hospital (Wuhu Fifth People\u2019s Hospital)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100332888","display_name":"Jingjing Chen","orcid":"https://orcid.org/0000-0002-1433-228X","observed_orcids":["https://orcid.org/0000-0002-1433-228X"]},"institutions":[{"id":"https://openalex.org/I4210136596","display_name":"First Affiliated Hospital of Anhui Medical University","ror":"https://ror.org/03t1yn780","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210136596"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jingjing Chen","raw_affiliation_strings":["Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University","institution_ids":["https://openalex.org/I4210136596"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113318422","display_name":"Caicong You","orcid":"https://orcid.org/0009-0005-5252-5647","observed_orcids":["https://orcid.org/0009-0005-5252-5647"]},"institutions":[{"id":"https://openalex.org/I129708740","display_name":"Fujian Medical University","ror":"https://ror.org/050s6ns64","country_code":"CN","type":"education","lineage":["https://openalex.org/I129708740"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Caicong You","raw_affiliation_strings":["School of Pharmacy, Fujian Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, Fujian Medical University","institution_ids":["https://openalex.org/I129708740"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5113318422"],"corresponding_institution_ids":["https://openalex.org/I129708740"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.76521357,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1938259","last_page":"1938259"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9384999871253967,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9384999871253967,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10882","display_name":"Cardiomyopathy and Myosin Studies","score":0.05790000036358833,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aficamten","display_name":"aficamten","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hypertrophic-obstructive-cardiomyopathy","display_name":"hypertrophic obstructive cardiomyopathy","score":0.996999979019165},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9959999918937683},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8949999809265137},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7409999966621399},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.7799999713897705},{"id":"https://openalex.org/keywords/drug-price-reduction","display_name":"drug price reduction","score":0.5720000267028809},{"id":"https://openalex.org/keywords/chinese-healthcare-system","display_name":"Chinese healthcare system","score":0.8220000267028809}],"concepts":[{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8274000287055969},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8241000175476074},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.5169000029563904},{"id":"https://openalex.org/C12713177","wikidata":"https://www.wikidata.org/wiki/Q1900281","display_name":"Perspective (graphical)","level":2,"score":0.46790000796318054},{"id":"https://openalex.org/C2988170871","wikidata":"https://www.wikidata.org/wiki/Q11000047","display_name":"Healthcare system","level":3,"score":0.4507000148296356},{"id":"https://openalex.org/C49937458","wikidata":"https://www.wikidata.org/wiki/Q2599292","display_name":"Probabilistic logic","level":2,"score":0.44209998846054077},{"id":"https://openalex.org/C163836022","wikidata":"https://www.wikidata.org/wiki/Q6771326","display_name":"Markov model","level":3,"score":0.42419999837875366},{"id":"https://openalex.org/C21200559","wikidata":"https://www.wikidata.org/wiki/Q7451068","display_name":"Sensitivity (control systems)","level":2,"score":0.37139999866485596},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3513999879360199},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.33889999985694885},{"id":"https://openalex.org/C98763669","wikidata":"https://www.wikidata.org/wiki/Q176645","display_name":"Markov chain","level":2,"score":0.32760000228881836},{"id":"https://openalex.org/C2777364431","wikidata":"https://www.wikidata.org/wiki/Q140813","display_name":"Willingness to pay","level":2,"score":0.3174999952316284},{"id":"https://openalex.org/C184834754","wikidata":"https://www.wikidata.org/wiki/Q358564","display_name":"Cost\u2013utility analysis","level":3,"score":0.3125999867916107},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30070000886917114},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.2870999872684479},{"id":"https://openalex.org/C66887028","wikidata":"https://www.wikidata.org/wiki/Q382444","display_name":"Marginal cost","level":2,"score":0.2687999904155731},{"id":"https://openalex.org/C2987370644","wikidata":"https://www.wikidata.org/wiki/Q7836903","display_name":"Treatment effect","level":2,"score":0.2578999996185303},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.25690001249313354},{"id":"https://openalex.org/C2779900020","wikidata":"https://www.wikidata.org/wiki/Q6015473","display_name":"Incremental cost-effectiveness ratio","level":4,"score":0.2526000142097473}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2026.1938259","doi":"https://doi.org/10.3389/fphar.2026.1938259","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938259","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938259/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13683131","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13683131/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13683131/pdf/fphar-17-1938259.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmid:42908723","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42908723","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:3a1c78d8263f4783b2a1bcd48cc1e6aa","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/3a1c78d8263f4783b2a1bcd48cc1e6aa","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1938259","doi":"https://doi.org/10.3389/fphar.2026.1938259","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938259","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938259/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220839703.pdf","grobid_xml":"https://content.openalex.org/works/W7220839703.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1963531403","https://openalex.org/W3081778241","https://openalex.org/W3093924829","https://openalex.org/W4200116546","https://openalex.org/W4206121490","https://openalex.org/W4283804747","https://openalex.org/W4293282124","https://openalex.org/W4313429960","https://openalex.org/W4313478485","https://openalex.org/W4386152544","https://openalex.org/W4387432042","https://openalex.org/W4388033955","https://openalex.org/W4396750647","https://openalex.org/W4396871808","https://openalex.org/W4405752122","https://openalex.org/W4411288245","https://openalex.org/W4411568114","https://openalex.org/W4412543799","https://openalex.org/W4413841879","https://openalex.org/W7130731903","https://openalex.org/W7133722905"],"related_works":["https://openalex.org/W7130731903","https://openalex.org/W4411568114","https://openalex.org/W7163931382","https://openalex.org/W4416379285","https://openalex.org/W4415723122","https://openalex.org/W7166448997","https://openalex.org/W4409070359","https://openalex.org/W4402987720","https://openalex.org/W4311333024","https://openalex.org/W4402111483"],"abstract_inverted_index":{"Background:":[0],"To":[1],"evaluate":[2],"the":[3,24,27,38,68,153,166,207,221,227,244],"cost-effectiveness":[4],"of":[5,9,26,72,141,150,156,160,173,199,216],"aficamten":[6,73,120,232],"plus":[7,121,135,233],"standard":[8],"care":[10],"(SoC)":[11],"versus":[12,237],"SoC":[13,122,126,136,234,238],"alone":[14,239],"for":[15,62,240],"patients":[16],"with":[17,119,125,128],"symptomatic":[18,241],"obstructive":[19],"hypertrophic":[20],"cardiomyopathy":[21],"(oHCM)":[22],"from":[23],"perspective":[25],"Chinese":[28,228],"healthcare":[29,229],"system.":[30],"Methods:":[31],"A":[32],"four-state":[33],"Markov":[34],"model":[35],"based":[36],"on":[37,66],"phase":[39],"III":[40],"SEQUOIA-HCM":[41],"trial":[42,56],"was":[43,74,102,163,223,235],"developed":[44],"to":[45,76,85,147],"simulate":[46],"lifetime":[47],"outcomes.":[48],"The":[49,158],"first":[50],"24":[51],"weeks":[52],"were":[53,95,117,179,204],"modeled":[54],"using":[55,104],"data,":[57],"followed":[58],"by":[59,88],"4-week":[60,219],"cycles":[61],"long-term":[63],"extrapolation.":[64],"Based":[65],"FOREST-HCM,":[67],"incremental":[69,139],"treatment":[70,183],"effect":[71],"assumed":[75],"persist":[77],"through":[78],"week":[79],"96":[80],"and":[81,92,111,123,130,143,189,201],"then":[82],"linearly":[83],"wane":[84],"complete":[86],"loss":[87],"year":[89,187,195],"3.":[90],"Costs":[91],"health":[93],"outcomes":[94],"discounted":[96],"at":[97,165],"4.5%":[98],"annually.":[99],"Model":[100],"uncertainty":[101],"assessed":[103],"one-way":[105],"sensitivity":[106,109],"analysis,":[107,110],"probabilistic":[108],"scenario":[112],"analyses.":[113],"Results:":[114],"Total":[115],"costs":[116],"US$143,281.22":[118],"US$96,509.03":[124],"alone,":[127],"9.696":[129],"7.643":[131],"QALYs,":[132,145],"respectively.":[133],"Aficamten":[134],"yielded":[137],"an":[138,148],"cost":[140],"US$46,772.19":[142],"2.054":[144],"corresponding":[146],"ICER":[149,222],"US$22,775.17/QALY,":[151],"below":[152],"WTP":[154,167],"threshold":[155],"US$29,399.70/QALY.":[157],"probability":[159,215],"being":[161],"cost-effective":[162,236],"76.6%":[164],"threshold.":[168],"Scenario":[169],"analyses":[170],"showed":[171],"ICERs":[172],"US$19,351.77/QALY":[174],"when":[175,182,191],"only":[176],"short-term":[177],"effects":[178,184],"considered,":[180],"US$43,752.42/QALY":[181],"disappeared":[185,193],"in":[186,194,206],"5,":[188],"US$81,220.72/QALY":[190],"they":[192],"10.":[196],"Price":[197],"reductions":[198],"22.0%":[200],"50.5%,":[202],"respectively,":[203],"required":[205],"latter":[208],"two":[209],"scenarios.":[210],"With":[211],"a":[212],"permanent":[213],"discontinuation":[214],"0.131%":[217],"per":[218],"cycle,":[220],"US$23,888.94/QALY.":[224],"Conclusion:":[225],"From":[226],"system":[230],"perspective,":[231],"oHCM":[242],"under":[243],"base-case":[245],"assumptions.":[246]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-10-08T00:00:00"}